The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).
 
Masashi Kanai
Stock and Other Ownership Interests - Therabiopharma Inc.
Honoraria - Chugai Pharma
Patents, Royalties, Other Intellectual Property - JMS Co.Ltd; Therabiopharma Inc.
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Kenji Tsuchihashi
Honoraria - Bayer; Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ryunosuke Machida
No Relationships to Disclose
 
Ryo Sadachi
No Relationships to Disclose
 
Akihiro Hirakawa
Consulting or Advisory Role - Abbvie; Astellas Amgen BioPharama; Chugai Pharma; Kissei Pharmaceutical; Kyowa Kirin; Nippon Shinyaku; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - Chugai Pharma
 
Masahisa Kamikura
No Relationships to Disclose
 
Kenta Anjo
No Relationships to Disclose
 
Shigeki Sekine
No Relationships to Disclose
 
Natsuko Tsuda Okita
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)